View Older Stories View More Recent Stories
-
Ionis Pharmaceuticals (IONS) PT Raised to $92 at Guggenheim
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $83 at BofA Securities
-
Ionis reports positive results for Alexander disease drug zilganersen
-
Ionis Pharmaceuticals (IONS) Halted, News Pending
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
TRYNGOLZA approved in Europe for rare genetic syndrome FCS
-
Ionis expands adaptive event for neurological disease communities
-
Ionis Pharmaceuticals (IONS) PT Raised to $80 at RBC Capital
-
Ionis Pharmaceuticals (IONS) PT Raised at Bernstein Following 'Positive Topline Results'
-
Ionis Pharmaceuticals (IONS) PT Raised to $95 at H.C. Wainwright
-
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform
-
Ionis Pharmaceuticals (IONS) spreader of 5K contracts of September 55 calls and puts as share price up 35%
-
Ionis Pharmaceuticals (IONS) PT Raised to $81 at Oppenheimer
-
Stifel Reiterates Ionis Pharmaceuticals (IONS) at Hold, 'a highly-positive outcome for IONS'
-
Ionis olezarsen shows 72% triglyceride reduction in Phase 3 studies
-
Ionis Pharmaceuticals (IONS) PT Raised at Piper Sandler Following FDA Approval
-
Ionis Pharmaceuticals (IONS) PT Raised to $70 at H.C. Wainwright
-
Ionis Pharmaceuticals (IONS) PT Raised to $82 at Wells Fargo
-
Ionis Pharmaceuticals (IONS) PT Raised to $69 at Citi
-
Ionis Pharmaceuticals (IONS) PT Raised to $64 at BofA Securities
-
Ionis Pharmaceuticals (IONS) PT Raised to $43 at Stifel
-
BMO Capital Reiterates Market Perform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) Halted, News Pending
-
Jefferies Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $65 at H.C. Wainwright
-
Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS) to Overweight
-
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 94c ; Offers Guidance
-
Ionis drug TRYNGOLZA gets EU committee approval recommendation for rare disease
-
Barclays Upgrades Ionis Pharmaceuticals (IONS) to Overweight
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
-
Biogen (BIIB) to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
-
Ionis Pharmaceuticals (IONS) Announces Retirement of Chief Development Officer
-
Ionis Pharmaceuticals (IONS): First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
-
Stifel Reiterates Hold Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
-
Ionis Pharmaceuticals (IONS) PT Raised to $50 at H.C. Wainwright
-
Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 15c ; Offers Guidance
-
H.C. Wainwright Starts Ionis Pharmaceuticals (IONS) at Buy
-
Redburn-Atlantic Starts Ionis Pharmaceuticals (IONS) at Neutral
-
UBS Reiterates Neutral Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) expands partnership with Sobi to include olezarsen commercialization outside the U.S.
-
Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) and Ono announce global license agreement
-
Ionis Pharmaceuticals (IONS) Announces WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
-
Ionis Pharmaceuticals (IONS) PT Lowered to $43 at Bernstein SocGen Group
-
Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at AAAAI/WAO
-
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
-
Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel
